| Literature DB >> 27107819 |
Huda S Al-Salem1, Ramesa Shafi Bhat2, Laila Al-Ayadhi3,4,5, Afaf El-Ansary6,7,8,9.
Abstract
BACKGROUND: It is now well documented that postnatal exposure to certain chemicals has been reported to increase the risk of autism spectrum disorder. Propionic acid (PA), as a metabolic product of gut microbiotaandas a commonly used food additive, has been reported to mediate the effects of autism. Results from animal studies may help to identify environmental neurotoxic agents and drugs that can ameliorate neurotoxicity and may thereby aid in the treatment of autism. The present study investigated the ameliorative effects of natural bee pollen against acute and sub-acute brain intoxication induced by (PA) in rats.Entities:
Keywords: Autism; Bee pollen; Caspase 3; Interferon gamma; Neurotransmitters; Propionic acid
Mesh:
Substances:
Year: 2016 PMID: 27107819 PMCID: PMC4842259 DOI: 10.1186/s12906-016-1099-8
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
The mean ± S.D and percentage changes of the four measured parameters in brain homogenates of PPA-acute and sub-acuteintoxicated rats and pollen-treated rats in comparisonwiththecontrol animals
| Parameter | Group | N | Mean ± S.D. | Percent change |
|
|
|---|---|---|---|---|---|---|
| IF ϒ (pg/100 mg) | Control | 6 | 82.82 ± 7.52 | 100.00 | ||
| PPA-acute | 6 | 123.05 ± 6.58 | 148.57 | 0.001 | ||
| PPA-sub-acute | 6 | 102.60 ± 5.08 | 123.87 | 0.001 | 0.001 | |
| Pollen | 6 | 87.40 ± 2.09 | 105.52 | 0.203 | 0.001 | |
| Nor-adrenaline (ng/100 mg) | Control | 6 | 4.92 ± 0.61 | 100.00 | ||
| PPA-acute | 6 | 3.25 ± 0.36 | 66.12 | 0.001 | ||
| PPA-sub-acute | 6 | 2.88 ± 0.32 | 58.49 | 0.001 | 0.086 | |
| Pollen | 6 | 3.79 ± 0.15 | 77.18 | 0.005 | 0.013 | |
| 5-HT (ng/100 mg) | Control | 6 | 6.20 ± 0.78 | 100.00 | ||
| PPA-acute | 6 | 3.78 ± 0.56 | 61.00 | 0.001 | ||
| PPA-sub-acute | 6 | 3.11 ± 0.18 | 50.07 | 0.001 | 0.029 | |
| Pollen | 6 | 4.36 ± 0.42 | 70.36 | 0.005 | 0.069 | |
| Dopamine (ng/100 mg) | Control | 6 | 21.12 ± 2.72 | 100.00 | ||
| PPA-acute | 6 | 13.69 ± 0.80 | 64.81 | 0.001 | ||
| PPA-sub-acute | 6 | 11.17 ± 1.29 | 52.92 | 0.001 | 0.002 | |
| Pollen | 6 | 16.09 ± 0.71 | 76.20 | 0.005 | 0.001 | |
| Caspase 3 (u/100 mg) | Control | 6 | 112.66 ± 4.20 | 100.00 | ||
| PPA-acute | 6 | 134.79 ± 3.27 | 119.65 | 0.001 | ||
| PPA-sub-acute | 6 | 152.57 ± 8.97 | 135.43 | 0.001 | 0.003 | |
| Pollen | 6 | 124.23 ± 2.89 | 110.28 | 0.001 | 0.001 |
*P value between control group and other groups
**P value between PPA-acute group and other groups
Fig. 1Percentage change of all parameters in all groups in comparisonwith the control
Pearson correlations between the measured parameters
| Parameters | R (Person correlation) | Sig. | |
|---|---|---|---|
| IFϒ ~ Nor-adrenaline | −0.665c | 0.001 | Nb |
| IFϒ ~ 5-HT | −0.582c | 0.003 | Nb |
| IFϒ ~ Dopamine | −0.604c | 0.002 | Nb |
| IFϒ ~ Caspase 3 | 0.567c | 0.004 | Pa |
| Nor-adrenaline ~ 5-HT | 0.817c | 0.001 | Pa |
| Nor-adrenaline ~ Dopamine | 0.864c | 0.001 | Pa |
| Nor-adrenaline ~ Caspase 3 | −0.781c | 0.001 | Nb |
| 5-HT ~ Dopamine | 0.935c | 0.001 | Pa |
| 5-HT ~ Caspase 3 | −0.850c | 0.001 | Nb |
| Dopamine ~ Caspase 3 | −0.870c | 0.001 | Nb |
aPositive Correlation
bNegative Correlation
cCorrelation is significant at the 0.01 level
Fig. 2Pearson’s positive and negative correlations with best-fit line curves between the measured parameters. a IFϒ and nor-adrenaline (−ve), b IFϒ and 5-HT (−ve), c IFϒ and dopamine(−ve), d IFϒ and caspase 3 (+ve), e nor-adrenaline and 5-HT(+ve), f noradrenaline and dopamine (+ve), g nor-adrenaline and caspase 3(−ve), h 5-HT and dopamine (+ve), i 5-HT and caspase 3 (− ve), and j dopamine and caspase 3 (−ve)
Fig. 3ROC Curve of a all parameters in the PPA-acute group, b all parameters in the PPA-sub-acute group, and c all parameters in the pollen group
ROC curve of the measured parameters in acute, sub-acute and pollen-treated groups in all groups
| Group | Area under the curve | Best Cutoff value | Sensitivity % | Specificity % | |
|---|---|---|---|---|---|
| IFϒ (pg/100 mg) | PPA-acute | 1.000 | 111.370 | 100.0 % | 100.0 % |
| PPA- sub-acute | 0.667 | 94.260 | 100.0 % | 66.7 % | |
| Pollen | 0.769 | 91.450 | 100.0 % | 72.2 % | |
| Nor-adrenaline (ng/100 mg) | PPA-acute | 0.741 | 3.685 | 100.0 % | 61.1 % |
| PPA- sub-acute | 0.912 | 3.360 | 100.0 % | 83.3 % | |
| Pollen | 0.653 | 3.510 | 100.0 % | 55.6 % | |
| 5-HT (ng/100 mg) | PPA-acute | 0.639 | 4.450 | 100.0 % | 50.0 % |
| PPA- sub-acute | 0.954 | 3.585 | 100.0 % | 88.9 % | |
| Pollen | 0.593 | 3.840 | 100.0 % | 50.0 % | |
| Dopamine (ng/100 mg) | PPA-acute | 0.676 | 15.005 | 100.0 % | 66.7 % |
| PPA- sub-acute | 0.991 | 12.920 | 100.0 % | 94.4 % | |
| Pollen | 0.667 | 15.005 | 100.0 % | 66.7 % | |
| Caspase 3 (u/100 mg) | PPA-acute | 0.667 | 129.310 | 100.0 % | 66.7 % |
| PPA- sub-acute | 1.000 | 140.835 | 100.0 % | 100.0 % | |
| Pollen | 0.667 | 129.310 | 100.0 % | 66.7 % |
Fig. 4Schematic presentation of the experimental work demonstrating treatment of different studied groups